Evaluation of gene expression, methylation and secretory level of cytokines and inflammatory chemokines in COPD patients receiving nanocurcumin supplementation compared with patients receiving placebo

Phase 3

• Conditions: Chronic Obstructive Pulmonary Disease (COPD).; Other chronic obstructive pulmonary disease

• Registration Number: IRCT20200324046851N2
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Diagnosed with COPD with stage B, C, or D according to GOLD 2019..
Age between 40-75 years old.
Both genders.
Smoker or less than 6 months of smoking cessation time

Exclusion Criteria

Asthma and other pulmonary-related diseases and injuries (including lung tuberculosis, restrictive lung disease, idiopathic pulmonary fibrosis, or lung cancer).
Acute and/or active infection.
Cancer.
Patients with complex cardiovascular diseases (including valvular heart disease, cardiomyopathy, arrhythmia, congenital heart disease, hypertrophy syndrome).
Liver and kidney failure.
Pregnancy.
Patients with life expectancy less than 6 months due to concomitant illness.
Under immunosuppressive treatment within 8 weeks of the first screening visit

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IL-1. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;CCL2. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;CXCL8. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;IL-6. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;IL-18. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;IFN-?. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;TNF-a. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.